Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Capital Expenditures (2024 - 2026)

Kestra Medical Technologies (KMTS) reported Capital Expenditures of $9.8 million for Q1 2026, up 205.75% year-over-year from $3.2 million in Q1 2025, and up 34.85% on a QoQ basis from $7.3 million in Q4 2025.

Kestra Medical Technologies (KMTS) has 3 years of Capital Expenditures data on file, last reported at $9.8 million in Q1 2026.

  • Quarterly Capital Expenditures rose 205.75% year-over-year to $9.8 million in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $24.9 million (up 293.16% YoY) and the FY2025 annual result came in at $1.9 million, down 84.66% from the prior year.
  • Capital Expenditures climbed to $9.8 million in Q1 2026 per KMTS's latest filing, from $7.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $9.8 million in Q1 2026 and bottomed at -$9.3 million in Q1 2025.
  • The 3-year median for Capital Expenditures is $5.7 million (2024), against an average of $3.9 million.
  • The widest annual swing landed in 2025, when Capital Expenditures tumbled 108.4%; it then surged 205.75% in 2026.
  • Tracing KMTS's Capital Expenditures over 3 years: stood at $4.4 million in 2024, then surged by 63.37% to $7.3 million in 2025, then soared by 34.85% to $9.8 million in 2026.
  • Per Business Quant, the three latest KMTS Capital Expenditures figures stand at $9.8 million (Q1 2026), $7.3 million (Q4 2025), and $8.2 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn 103.30 Mn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn 125.00 Mn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn 33.65 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn 26.10 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn 84.00 Mn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn 102.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn 30.79 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn 137.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn 65.40 Mn
10 Kestra Medical Technologies 1.13 Bn 840.05 Mn 12.91 Mn 9.80 Mn

Historic Data

Download Data 🔒
DateValue
Jan 31, 2026 9.80 Mn
Jan 31, 2026 9.80 Mn
Oct 31, 2025 7.27 Mn
Oct 31, 2025 7.27 Mn
Jul 31, 2025 8.17 Mn
Jul 31, 2025 8.17 Mn
Apr 30, 2025 -345,000.00
Apr 30, 2025 -345,000.00
Jan 31, 2025 -9.26 Mn
Jan 31, 2025 -9.26 Mn
Oct 31, 2024 4.45 Mn
Oct 31, 2024 4.45 Mn
Jul 31, 2024 7.04 Mn
Jul 31, 2024 7.04 Mn
Apr 30, 2024 4.11 Mn
Apr 30, 2024 4.11 Mn